220 related articles for article (PubMed ID: 22834082)
21. Recent advances in protein and peptide drug delivery systems.
Malik DK; Baboota S; Ahuja A; Hasan S; Ali J
Curr Drug Deliv; 2007 Apr; 4(2):141-51. PubMed ID: 17456033
[TBL] [Abstract][Full Text] [Related]
22. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Wang X; Chi N; Tang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400
[TBL] [Abstract][Full Text] [Related]
23. Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly absorbable drugs in rats.
Dong Z; Katsumi H; Sakane T; Yamamoto A
Int J Pharm; 2010 Jun; 393(1-2):244-52. PubMed ID: 20417700
[TBL] [Abstract][Full Text] [Related]
24. An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting.
Wong CYJ; Baldelli A; Tietz O; van der Hoven J; Suman J; Ong HX; Traini D
Int J Pharm; 2024 Apr; 654():123922. PubMed ID: 38401871
[TBL] [Abstract][Full Text] [Related]
25. Intranasal drug delivery: how, why and what for?
Pires A; Fortuna A; Alves G; Falcão A
J Pharm Pharm Sci; 2009; 12(3):288-311. PubMed ID: 20067706
[TBL] [Abstract][Full Text] [Related]
26. Recent trends in drug delivery systems: intranasal drug delivery.
Agarwal V; Mishra B
Indian J Exp Biol; 1999 Jan; 37(1):6-16. PubMed ID: 10355359
[TBL] [Abstract][Full Text] [Related]
27. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Shah B; Khunt D; Misra M; Padh H
Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
[TBL] [Abstract][Full Text] [Related]
28. Intranasal drug delivery for brain targeting.
Vyas TK; Shahiwala A; Marathe S; Misra A
Curr Drug Deliv; 2005 Apr; 2(2):165-75. PubMed ID: 16305417
[TBL] [Abstract][Full Text] [Related]
29. In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.
Ghosh A; Majie A; Karmakar V; Chatterjee K; Chakraborty S; Pandey M; Jain N; Roy Sarkar S; Nair AB; Gorain B
AAPS PharmSciTech; 2024 May; 25(5):96. PubMed ID: 38710855
[TBL] [Abstract][Full Text] [Related]
30. Drug delivery systems from nose to brain.
Misra A; Kher G
Curr Pharm Biotechnol; 2012 Sep; 13(12):2355-79. PubMed ID: 23016642
[TBL] [Abstract][Full Text] [Related]
31. Formulation and physiological factors influencing CNS delivery upon intranasal administration.
Vyas TK; Tiwari SB; Amiji MM
Crit Rev Ther Drug Carrier Syst; 2006; 23(4):319-47. PubMed ID: 17341201
[TBL] [Abstract][Full Text] [Related]
32. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development.
Wen MM
Discov Med; 2011 Jun; 11(61):497-503. PubMed ID: 21712015
[TBL] [Abstract][Full Text] [Related]
33. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery.
Alex AT; Joseph A; Shavi G; Rao JV; Udupa N
Drug Deliv; 2016 Sep; 23(7):2144-2153. PubMed ID: 25544603
[TBL] [Abstract][Full Text] [Related]
34. Review: clinical opportunities provided by the nasal administration of peptides.
Harris AS
J Drug Target; 1993; 1(2):101-16. PubMed ID: 8069548
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of allergens after local administration.
Falagiani P; Mistrello G
Allergy; 1997; 52(33 Suppl):17-21. PubMed ID: 9188942
[TBL] [Abstract][Full Text] [Related]
36. Quantitative Estimation of the Effect of Nasal Mucociliary Function on in Vivo Absorption of Norfloxacin after Intranasal Administration to Rats.
Inoue D; Kimura S; Kiriyama A; Katsumi H; Yamamoto A; Ogawara KI; Higaki K; Tanaka A; Yutani R; Sakane T; Furubayashi T
Mol Pharm; 2018 Oct; 15(10):4462-4469. PubMed ID: 30165013
[TBL] [Abstract][Full Text] [Related]
37. Development of a Transnasal Delivery System for Recombinant Human Growth Hormone (rhGH): Effects of the Concentration and Molecular Weight of Poly-L-arginine on the Nasal Absorption of rhGH in Rats.
Kawashima R; Uchida M; Yamaki T; Ohtake K; Hatanaka T; Uchida H; Ueda H; Kobayashi J; Morimoto Y; Natsume H
Biol Pharm Bull; 2016; 39(3):329-35. PubMed ID: 26725528
[TBL] [Abstract][Full Text] [Related]
38. Nanomedicines for intranasal delivery: understanding the nano-bio interactions at the nasal mucus-mucosal barrier.
Hua T; Li S; Han B
Expert Opin Drug Deliv; 2024 Apr; 21(4):553-572. PubMed ID: 38720439
[TBL] [Abstract][Full Text] [Related]
39. Aminated gelatin as a nasal absorption enhancer for peptide drugs: evaluation of absorption enhancing effect and nasal mucosa perturbation in rats.
Wang J; Sakai S; Deguchi Y; Bi D; Tabata Y; Morimoto K
J Pharm Pharmacol; 2002 Feb; 54(2):181-8. PubMed ID: 11848281
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms and solutions for nasal drug delivery - a narrative review.
Ulusoy S; Bayar Muluk N; Karpischenko S; Passali GC; Negm H; Passali D; Milkov M; Kopacheva-Barsova G; Konstantinidis I; Dilber M; Cingi C
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(2 Suppl):72-81. PubMed ID: 36524914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
